In this Weekly Supplement, IPQ relays a discussion at the June 2024 PDA ATMP conference by EMA Quality Head Veronika Jekerle of the interplay between the agency and ATMP developers. Jekerle focused, in particular, on gene therapies, including the recently approved CRISPR/Cas9 product Casgevy, and the CMC challenges that need to be addressed for these products.
Along with a feature story on a presentation given at a recently held conference by a leading regulator that addresses the challenges and developments in a key area of concern, our Weekly Supplements include a summary listing of the “Updates in Brief,” drug GMP warning letters and recalls, and EMA non-compliance reports that have been posted on IPQ’s website during the week. Subscribers can then click through to the full posting.
Also provided, where applicable, are links to the parts of in-depth stories and Monthly Updates that have been released during the week.
Appended to the issue is a chronological listing of the headlines of the in-depth stories that IPQ has released since 2020. Readers of the Weekly Supplement are invited to click through to those that are of particular relevance to the regulatory presentation, news briefs, or compliance developments provided in the issue. Those of especially high relevance to the featured regulator story are indicated with a red star.
